Descrizione del progetto
Biomarcatori biomeccanici per la previsione della risposta immunitaria
L’immunoterapia antitumorale provoca gravi tossicità in alcuni casi, sottolineando l’importanza di biomarcatori in grado di prevedere tempestivamente i pazienti non-responder. Per affrontare questo problema, il progetto Immuno-Predictor, finanziato dall’UE, sta lavorando con l’ipotesi che alcuni aspetti biomeccanici del microambiente tumorale, quali la rigidità del tumore, lo stress solido, la perfusione e l’ipossia, siano responsabili della resistenza all’immunoterapia. La somministrazione sistemica di immunoterapia richiede un sistema vascolare ben perfuso, e questo non è spesso il caso dei tumori rigidi e ipossici. Utilizzando metodi clinicamente applicati basati su ultrasuoni e modelli biomeccanici computazionali in topi portatori di tumore e in pazienti oncologici, gli scienziati di Immuno-Predictor identificheranno biomarcatori biomeccanici per prevedere l’esito dell’immunoterapia.
Obiettivo
Immunotherapy has revolutionized the treatment of multiple cancers and has already become a standard of care for some tumor types. However, a majority of patients do not benefit from current immunotherapeutics and many develop severe toxicities. Therefore, the identification of biomarkers to classify patients as likely responders or nonresponders to immunotherapy is a timely and of tremendous impact task. My hypothesis is that biomechanical aspects of the tumor microenvironment mediate resistance to immunotherapy. Specifically, many tumors stiffen as they grow and also, tumor growth within the host tissue generates mechanical forces, termed solid stress. Tumor stiffening and solid stress are distinct mechanical abnormalities that compress intratumoral blood vessels, causing hypo-perfusion and hypoxia. Systemic administration of immunotherapeutics requires a well-perfused vasculature, whereas hypo-perfusion and hypoxia promote immunosuppression, helping cancer cells to evade immune responses. The objective of the proposed research is the identification of novel Mechanical Biomarkers related to tumor stiffness, solid stress, perfusion and hypoxia for prediction of immunotherapy. Tumor-bearing mice will be developed and treated with immunotherapeutic drugs and clinically used methods will be combined with computational biomechanical modeling for measuring the Mechanical Biomarkers, making the research transferable to the clinic. The biomarkers will be benchmarked against tumor normalization strategies aiming to restore/normalize mechanical abnormalities and optimize immunotherapy. Finally, the clinical utility of the selected biomarkers will be evaluated in human tumors. Only few tumor-specific biomarkers are used in the clinic - based mainly on genomic analysis. This project is expected to lead to the first biomarkers for immunotherapy prediction exploiting tumor mechanics.
Campo scientifico
Programma(i)
Argomento(i)
Meccanismo di finanziamento
ERC-COG - Consolidator GrantIstituzione ospitante
1678 Nicosia
Cipro